Ocumension Therapeutics Gets Nod for Real World Study of Intravitreal Implant in China

MT Newswires Live

2025/05/14

Ocumension Therapeutics (HKG:1477) obtained approval to carry out a real world study of OT-703 (ILUVIEN) in Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China, a Tuesday Hong Kong bourse filing said.

OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema.

In April 2021, the drugmaker had obtained exclusive licensed rights from Alimera Sciences for the development and commercialization of ILUVIEN in Greater China, South Korea and 11 countries in Southeast Asia.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠：港股&Crypto 0佣、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2535095297"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535095297\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535095297?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 14:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535095297","market":"us","top_or_hot":-1,"title":"Ocumension Therapeutics Gets Nod for Real World Study of Intravitreal Implant in China","media":"MT Newswires Live","content":"<html><body><p> Ocumension <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:1477) obtained approval to carry out a real world study of OT-703 (ILUVIEN) in Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China, a Tuesday Hong Kong bourse filing said.</p><p>OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema.</p><p>In April 2021, the drugmaker had obtained exclusive licensed rights from Alimera Sciences for the development and commercialization of ILUVIEN in Greater China, South Korea and 11 countries in Southeast Asia.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocumension Therapeutics Gets Nod for Real World Study of Intravitreal Implant in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcumension Therapeutics Gets Nod for Real World Study of Intravitreal Implant in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-05-14 14:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Ocumension <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (HKG:1477) obtained approval to carry out a real world study of OT-703 (ILUVIEN) in Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China, a Tuesday Hong Kong bourse filing said.</p><p>OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema.</p><p>In April 2021, the drugmaker had obtained exclusive licensed rights from Alimera Sciences for the development and commercialization of ILUVIEN in Greater China, South Korea and 11 countries in Southeast Asia.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01477","symbol_name":"欧康维视生物-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2535095297","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535095297","pubTimestamp":1747203652,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ocumension Therapeutics  obtained approval to carry out a real world study of OT-703  in Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China, a Tuesday Hong Kong bourse filing said.OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema.In April 2021, the drugmaker had obtained exclusive licensed rights from Alimera Sciences for the development and commercialization of ILUVIEN in Greater China, South Korea and 11 countries in Southeast Asia.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01477":"欧康维视生物-B","BK4007":"制药","BK1191":"制药","BK4539":"次新股","LENZ":"Therapeutics","BK1574":"生物医药B类股","BK4139":"生物科技"},"translate_title":"Ocumension Therapeutics在中国玻璃体内植入物的真实世界研究获得认可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"01477":0.9},"content_text":"Ocumension Therapeutics (HKG:1477) obtained approval to carry out a real world study of OT-703 (ILUVIEN) in Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province, China, a Tuesday Hong Kong bourse filing said.OT-703 is an injectable, non-biodegradable fluocinolone acetate intravitreal implant for the treatment of diabetic macular edema.In April 2021, the drugmaker had obtained exclusive licensed rights from Alimera Sciences for the development and commercialization of ILUVIEN in Greater China, South Korea and 11 countries in Southeast Asia.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}